Loading
CRISPR and Genetic Engineering · Journal article
Human Gene Therapy · August 23, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage, uncontrolled proof-of-concept study demonstrating that simultaneous CRISPR-Cas9 knockout of CCR5, MOGS, and integrated HIV-1 proviral DNA sequences suppresses viral replication in ex vivo-infected peripheral blood mononuclear cells. The work is preliminary and lacks quantified efficacy data, in vivo validation, and clinical evidence; further preclinical development is stated as the next step.
In vitro and ex vivo uncontrolled cellular study. HIV-1-infected peripheral blood mononuclear human cells.. Intervention: Triple-target CRISPR-Cas9 knockout of CCR5, MOGS, and integrated HIV-1 proviral DNA sequences..
Combination knockout of CCR5, MOGS, and viral sequences profoundly reduces HIV-1 replication in HIV-1-infected peripheral blood mononuclear human cells ex vivo Strategy targets both viral and host factors: CCR5 (host cell entry receptor) and MOGS (glycoprotein processing enzyme that modifies gp120)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding is not yet clinically applicable. It represents an early mechanistic demonstration requiring substantial further development, including in vivo validation, safety assessment, delivery optimization, and clinical trials before any therapeutic use could be considered.
Early-stage in vitro and ex vivo proof-of-concept work demonstrating a novel triple-target CRISPR strategy, not yet tested in vivo or clinically, with no efficacy or safety data in human subjects.
As stated by the source record.
Quoted from the source exactly as published.
This finding is not yet clinically applicable. It represents an early mechanistic demonstration requiring substantial further development, including in vivo validation, safety assessment, delivery optimization, and clinical trials before any therapeutic use could be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Total elimination of replication-competent human immunodeficiency virus type 1 (HIV-1) remains a major clinical challenge, in part due to random integration of the proviral DNA into host cell chromosomes, which enables lifelong persistence and production of progeny. Although antiretroviral therapies (ARTs) suppress viral replication, they cannot eliminate integrated proviral DNA, which remains a fundamental obstacle to achieving a cure. To overcome this problem, we developed a combinatorial clustered regularly interspaced short palindromic repeats–Cas9 gene editing strategy to disrupt viral replication and inactivate host factors essential for HIV-1 entry and spread. This approach targets C-C chemokine receptor type 5 (CCR5), a chemokine receptor central to HIV-1 host cell entry, and mannosyl-oligosaccharide glucosidase (MOGS), a key enzyme in glycoprotein processing that modifies the HIV-1 envelope glycoprotein gp120, facilitating receptor engagement, viral entry, and morphogenesis of infectious virion. We demonstrate that our strategy, which includes editing of the integrated proviral DNA, in concert with two cellular genes whose products facilitate viral entry, results in robust suppression of viral replication in vitro and in ex vivo -infected cells. Using transmission electron microscopy, HIV-1 p24 ELISA, and GFP-based viral infection assays, we show that the combination knockout of CCR5, MOGS, and viral sequences profoundly reduces HIV-1 replication in an ex vivo cellular model, that is, HIV-1-infected peripheral blood mononuclear human cells, thus offering a pathway to launch further preclinical studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.